Otsuka buys Visterra for $430mm in cash
Otsuka Pharmaceutical Co. Ltd. agreed to pay $430mm in cash to acquire Visterra Inc., a privately held company developing antibody therapeutics for hard-to-treat diseases.
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.